MedTrace Logo

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Greece

NCT01363674 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2017-12-26

No results posted yet for this study

Summary

This is a National, Multicentre, Observational Registry to study adherence and long term outcomes of therapy in paediatric subjects using Easypod™ electromechanical device for growth hormone treatment from hospitals in Greece and to assess the level of adherence of subjects receiving SAIZEN® via Easypod™.

Conditions

  • Growth Disorders

Interventions

DEVICE

Easypod™

Saizen (Somatotropin) as per Summary of Product Characteristics administered by Easypod™

Sponsors & Collaborators

  • Merck A.E., Greece

    collaborator INDUSTRY

  • Merck KGaA, Darmstadt, Germany

    lead INDUSTRY

Principal Investigators

  • Medical Director · Merck A.E., Greece

Eligibility

Min Age
2 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • Greece

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01363674 on ClinicalTrials.gov